Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice

Lu,Yonggang; Zhang,Mingming; Zhao,Pei; Jia,Min; Liu,Bing; Jia,Qian; Guo,Jun; Dou,Lin; Li,Jian

doi:10.3892/mmr.2017.6646

Modified citrus pectin inhibits galectin-3 function to reduce atherosclerotic lesions in apoE-deficient mice

Authors:
- Yonggang Lu
- Mingming Zhang
- Pei Zhao
- Min Jia
- Bing Liu
- Qian Jia
- Jun Guo
- Lin Dou
- Jian Li
View Affiliations

Affiliations: Clinical Laboratory, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China, Neurology Department 2, Handan Central Hospital, Handan, Hebei 056001, P.R. China, Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, Ministry of Health, Beijing 100730, P.R. China
Published online on: May 29, 2017 https://doi.org/10.3892/mmr.2017.6646
Pages: 647-653
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Galectin-3 is a carbohydrate-binding lectin, which has been implicated in the modulation of atherosclerotic pathophysiology, and is highly expressed in monocytes, macrophages and endothelial cells within atherosclerotic plaques. Modified citrus pectin (MCP) is produced from citrus pectin via pH and temperature modifications, which break it into shorter, non‑branched, galactose‑rich carbohydrate chains. MCP is able to tightly bind with galectin‑3, via recognition of its carbohydrate recognition domain, and facilitates the modulation of galectin‑3‑induced bioactivity. The present study explored the effects of MCP on the initiation of atherosclerosis. Eight‑week‑old apolipoprotein E‑deficient mice were treated with 1% MCP and fed an atherogenic diet for 4 weeks. The effects of MCP on atherosclerotic initiation were determined by pathological analysis and scanning electron microscope (SEM) imaging. MCP treatment reduced the size of atherosclerotic lesion areas, which was accompanied by decreased numbers of macrophages and smooth muscle cells (SMCs). Furthermore, SEM examination of the surface of the atheroma‑prone vessel wall indicated that MCP treatment reduced endothelial injury. To analyze the effects of MCP on monocyte adhesion, firstly, oxidized‑low density lipoprotein and various concentrations of MCP (0.025, 0.05, 0.1 and 0.25%) were incubated with the human umbilical vein endothelial cells (HUVECs) for stimulation and following this, the U937 cells were plated onto the HUVECs. The results revealed that MCP reduced the adhesion of U937 monocytes to HUVECs, indicating the adhesion-inhibiting effects of MCP. In conclusion, the present study revealed that MCP, a galectin‑3 inhibitor, reduced the size of atherosclerotic lesions by inhibiting the adhesion of leucocytes to endothelial cells. Inhibition of galectin‑3 function may be a therapeutic strategy for the treatment of atherosclerosis.

View Figures

View References

1	Chistiakov DA, Revin VV, Sobenin IA, Orekhov AN and Bobryshev YV: Vascular endothelium: Functioning in norm, changes in atherosclerosis and current dietary approaches to improve endothelial function. Mini Rev Med Chem. 15:338–350. 2015. View Article : Google Scholar : PubMed/NCBI
2	Schäfer A and Bauersachs J: Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol. 6:52–60. 2008. View Article : Google Scholar : PubMed/NCBI
3	Blankenberg S, Barbaux S and Tiret L: Adhesion molecules and atherosclerosis. Atherosclerosis. 170:191–203. 2003. View Article : Google Scholar : PubMed/NCBI
4	Rao SP, Wang Z, Zuberi RI, Sikora L, Bahaie NS, Zuraw BL, Liu FT and Sriramarao P: Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. J Immunol. 179:7800–7877. 2007. View Article : Google Scholar : PubMed/NCBI
5	Soehnlein O: Multiple roles for neutrophils in atherosclerosis. Circ Res. 110:875–888. 2012. View Article : Google Scholar : PubMed/NCBI
6	Nieminen J, St-Pierre C, Bhaumik P, Poirier F and Sato S: Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by Streptococcus pneumoniae. J Immunol. 180:2466–2473. 2008. View Article : Google Scholar : PubMed/NCBI
7	Tadokoro T, Ikekita M, Toda T, Ito H, Sato T, Nakatani R, Hamaguchi Y and Furukawa K: Involvement of Galectin-3 with vascular cell adhesion molecule-1 in growth regulation of mouse BALB/3T3 cells. J Biol Chem. 284:35556–35563. 2009. View Article : Google Scholar : PubMed/NCBI
8	Inohara H, Akahani S, Koths K and Raz A: Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 56:4530–4534. 1996.PubMed/NCBI
9	Sasaki T, Brakebusch C, Engel J and Timpl R: Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fibronectin. EMBO J. 17:1606–1613. 1998. View Article : Google Scholar : PubMed/NCBI
10	Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, Hirashima M and Liu FT: Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol. 165:2156–2164. 2000. View Article : Google Scholar : PubMed/NCBI
11	Hopkins PN: Molecular biology of atherosclerosis. Physiol Rev. 93:1317–1542. 2013. View Article : Google Scholar : PubMed/NCBI
12	Tekabe Y, Li Q, Rosario R, Sedlar M, Majewski S, Hudson BI, Einstein AJ, Schmidt AM and Johnson LL: Development of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis. Circ Cardiovasc Imaging. 1:212–219. 2008. View Article : Google Scholar : PubMed/NCBI
13	Gao X, Zhi Y, Zhang T, Xue H, Wang X, Foday AD, Tai G and Zhou Y: Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3. Glycoconj J. 29:159–165. 2012. View Article : Google Scholar : PubMed/NCBI
14	Nachtigal M, Ghaffar A and Mayer EP: Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol. 172:247–255. 2008. View Article : Google Scholar : PubMed/NCBI
15	Jacob SS, Shastry P and Sudhakaran PR: Monocyte-macrophage differentiation in vitro: Modulation by extracellular matrix protein substratum. Mol Cell Biochem. 233:9–17. 2002. View Article : Google Scholar : PubMed/NCBI
16	MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ and Sethi T: Regulation of alternative macrophage activation by galectin-3. J Immunol. 180:2650–2658. 2008. View Article : Google Scholar : PubMed/NCBI
17	Walski M, Chlopicki S, Celary-Walska R and Frontczak-Baniewicz M: Ultrastructural alterations of endothelium covering advanced atherosclerotic plaque in human carotid artery visualized by scanning electron microscope. J Physiol Pharmacol. 53:713–723. 2002.PubMed/NCBI
18	Nathan L, Pervin S, Singh R, Rosenfeld M and Chaudhuri G: Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo: Possible mechanisms for gender differences in atherosclerosis. Circ Res. 85:377–385. 1999. View Article : Google Scholar : PubMed/NCBI
19	MacKinnon AC, Liu X, Hadoke PW, Miller MR, Newby DE and Sethi T: Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology. 23:654–663. 2013. View Article : Google Scholar : PubMed/NCBI
20	Swarte VV, Mebius RE, Joziasse DH, Van den Eijnden DH and Kraal G: Lymphocyte triggering via L-selectin leads to enhanced galectin-3-mediated binding to dendritic cells. Eur J Immunol. 28:2864–2871. 1998. View Article : Google Scholar : PubMed/NCBI
21	Funasaka T, Raz A and Nangia-Makker P: Galectin-3 in angiogenesis and metastasis. Glycobiology. 24:886–891. 2014. View Article : Google Scholar : PubMed/NCBI
22	Hynes RO: The extracellular matrix: Not just pretty fibrils. Science. 326:1216–1219. 2009. View Article : Google Scholar : PubMed/NCBI
23	Hashiba K, Sano M, Nio-Kobayashi J, Hojo T, Skarzynski DJ and Okuda K: Galectin-3 contributes to luteolysis by binding to Beta 1 integrin in the bovine corpus luteum. Biol Reprod. 91:22014. View Article : Google Scholar : PubMed/NCBI
24	Hatley ME, Srinivasan S, Reilly KB, Bolick DT and Hedrick CC: Increased production of 12/15 lipoxygenase eicosanoids accelerates monocyte/endothelial interactions in diabetic db/db mice. J Biol Chem. 278:25369–25375. 2003. View Article : Google Scholar : PubMed/NCBI
25	Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW and Milstone DS: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 107:1255–1262. 2001. View Article : Google Scholar : PubMed/NCBI
26	Ingber DE: Cellular tensegrity: Defining new rules of biological design that govern the cytoskeleton. J Cell Sci. 104:613–627. 1993.PubMed/NCBI